Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Keytruda is an immunotherapy drug that is used to treat different types of cancers. The drug helps the body's own immune system to fight the cancer cells. Developed and sold by Merck & Co., the drug ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints, showing noninferiority to the intravenous formulation in metastatic NSCLC treatment. The subcutaneous formulation, administered ...

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...

The message Tolaney wants patients with newly diagnosed metastatic TNBC to take away from these findings is one of clarity ...

Moderna, Inc., a pioneer and leader in the field of mRNA medicine, and Merck, known as MSD outside of the United States and Canada, announced detailed results from a ...

Researchers found that Keytruda — the focus of ICIJ's recent Cancer Calculus investigation — accounted for nearly half of the ...

Most recurrences of the deadliest form of skin cancer develop within the first 2-3 years after treatment, but melanoma can recur even over a decade later, according to the AIM at Melanoma Foundation.